Adherence and Real-World Weight Loss Outcomes Medical experts have emphasized that adherence may be a key factor for patients choosing an oral GLP-1 medication
On December 22, 2025, Novo Nordisk announced that the U.S
Notably, around 30% of solid organ transplant recipients experience post-transplant diabetes[1]
Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials
Yes, some GLP-1 receptor agonists, such as liraglutide and semaglutide, have been shown to reduce the risk of major cardiovascular events in people with type 2 diabetes and cardiovascular disease
In the SURMOUNT-1 trial, tirzepatide demonstrated even more substantial results, with some participants losing over 20% of their starting weight